HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chism, S. E. Articles by Warner, N. L. Search for Related Content PubMed Articles by Chism, S. E. Articles by Warner, N. L.

Analysis of Murine Oncofetal Antigens as Tumor-Associated Transplantation Antigens¹

Genetics Unit, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

Abstract

In previous studies with in vitro activated cytotoxic T lymphocytes, we have demonstrated the presence of oncofetal antigens (OFA) on a range of murine tumor cells. The present studies with the same tumor lines attempt to determine whether these antigens are also capable of activating lymphocyte responses in vivo. Several experimental designs were followed, each being performed many times (1). Preimmunization of mice with irradiated fetal liver cells and followed by challenge with viable tumor cells did not consistently produce a state of tumor resistance. However, injection of live fetal cells frequently led to enhanced tumor growth (2). The growth of tumors in multiparous mice can be inhibited, in contrast to controls, but this effect was relatively short lived after parturition (3). Preimmunization with fetal cells in vivo did not result in augmented secondary cytotoxic T cell responses in vitro (4). Immunization of mice with irradiated tumor cells frequently led to a state of resistance to the clonal growth of hemopoietic fetal cells, although again the level of resistance was usually relatively weak. From the overall results, we conclude that OFA are relatively poor immunogens on tumor cells or fetal cells in vivo, and in contrast to in vitro responses, do not act as potent tumor transplantation antigens.

Footnotes

¹ This work was supported by research grants from the United States Public Health Service (CA-15600), National Cancer Institute; the Wellcome Foundation U.K.; and the National Health and Medical Research Council, Australia. This is Publication No. 2217 from The Walter and Eliza Hall Institute.

² Postdoctoral Research Fellow from the Division of Radiation Oncology, University of California, San Francisco (present address).